CJ Bioscience, Inc. (KOSDAQ:311690)

Market Cap	133.92B
Revenue (ttm)	3.47B
Net Income (ttm)	-32.84B
Shares Out	13.07M
EPS (ttm)	-3,541.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,320
Average Volume	17,762
Open	10,180
Previous Close	10,080
Day's Range	10,080 - 10,350
52-Week Range	8,250 - 18,800
Beta	0.80
RSI	47.91
Earnings Date	May 14, 2025

About CJ Bioscience

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company’s platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson’s diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics a...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 2009
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 311690

Financial Performance

In 2024, CJ Bioscience's revenue was 3.47 billion, a decrease of -37.82% compared to the previous year's 5.58 billion. Losses were -32.84 billion, 43.3% more than in 2023.